Imbalance between HAT and HDAC Activities in the PBMCs of Patients with Ankylosing Spondylitis or Rheumatoid Arthritis and Influence of HDAC Inhibitors on TNF Alpha Production

Eric Toussirot1,2,3,4*, Wasim Abbas4,5, Kashif Aziz Khan4,5, Marion Tissot6, Alicia Jeudy6, Lucile Baud6, Ewa Bertolini2, Daniel Wendling2,4, Georges Herbein4,5

1 Clinical Investigation Center Biotherapy CBT-506, University Hospital of Besançon, Besançon, France, 2 Department of Rheumatology, University Hospital of Besançon, Besançon, France, 3 Department of Therapeutics, University of Franche Comté, Besançon, France, 4 UPRES EA 4266, Pathogens and Inflammation Laboratory, SFR FED 2344, University of Franche Comté, Besançon, France, 5 Department of Virology, University Hospital of Besançon, Besançon, France

Abstract

Objective: Acetylation or deacetylation of histone proteins may modulate cytokine gene transcription such as TNF alpha (TNF). We evaluated the balance between histone deacetylase (HDAC) and histone acetyltransferase (HAT) in patients with rheumatoid arthritis (RA) or ankylosing spondylitis (AS) compared to healthy controls (HC) and determined the influence of HDAC inhibitors (trichostatin A -TSA- or Sirtinol -Sirt-) on these enzymatic activities and on the PBMC production of TNF.

Methods: 52 patients with RA, 21 with AS and 38 HC were evaluated. HAT and HDAC activities were measured on nuclear extracts from PBMC using colorimetric assays. Enzymatic activities were determined prior to and after ex vivo treatment of PBMC by TSA or Sirt. TNF levels were evaluated in PBMC culture supernatants in the absence or presence of TSA or Sirt.

Results: HAT and HDAC activities were significantly reduced in AS, while these activities reached similar levels in RA and HC. Ex vivo treatment of PBMC by HDACi tended to decrease HDAC expression in HC, but Sirt significantly reduced HAT in RA. TNF production by PBMC was significantly down-regulated by Sirt in HC and AS patients.

Conclusion: HAT and HDAC were disturbed in AS while no major changes were found in RA. HDACi may modulate HDAC and HAT PBMC expression, especially Sirt in RA. Sirtinol was able to down regulate TNF production by PBMC in HC and AS. An imbalance between HAT and HDAC activities might provide the rationale for the development of HDACi in the therapeutic approach to inflammatory rheumatic diseases.
Low disease activity was defined by a DAS28 < 3.2, moderate follow-up at the department of Rheumatology in the University Hospital of Besançon, France. In RA, disease activity and therapeutic interventions. Accumulating evidence suggests that epigenetic modifications can modulate gene transcription and thus could regulate the production of pro-inflammatory cytokines [1]. The epigenetic phenomenon refers to different biochemical reactions on the DNA without changing its sequence, including histone modifications [2,3]. These changes in histone proteins involve various reactions such as methylation, ubiquitination, phosphorylation, sumoylation and acetylation. Acetylation is certainly the best characterized post-translational modification of core histones. Histone acetylation is catalyzed by histone acetyltransferase (HAT) while deacetylation is influenced by histone deacetylase (HDAC). It is accepted that acetylation of histones is associated with enhanced rates of gene transcription, while deacetylation represses gene expression by condensing the chromatin [3,4]. The ratio of HDAC on HAT may thus give insights into the rate of gene transcription. Four classes of HDAC have been identified: Class I HDACs (HDAC 1, 2, 3 and 8) are primarily located in the nucleus while Class II HDACs (HDAC 4,5,6,7,9) translocate from the cytoplasm to the nucleus. HDAC 11 is the only member of HDAC Class IV, and HDAC Class III, or sirtuins, is a distinct class of enzymatic activity dependent on NAD⁺ [5].

Histone deacetylase enzymes target histone proteins but also non-histone proteins. Indeed, HDAC activities can interfere with inflammatory signalling pathways, transcription factors and tumor suppressor genes, regulating cellular activation, proliferation and differentiation. Thus, HDAC inhibitors (HDACi) have been developed in cancer therapy in an attempt to inhibit cell proliferation and to induce cell cycle arrest or apoptosis [6]. However, besides these antineoplastic properties, HDACi have also been shown to display anti-inflammatory effects, ameliorating joint inflammation and regulating the production of a range of cytokines in animal models of RA [4,7].

The equilibrium between HDAC and HAT activities could thus be considered as a relevant marker for gene regulation, including those coding for pro-inflammatory cytokines such as TNF. There are limited results on the ratio of HDAC/HAT activity in patients with RA and other forms of arthritis including AS. In this study therefore, we aimed to evaluate the HDAC / HAT ratio in the peripheral blood of patients with RA or AS and to analyze the influence of HDACi on the production of TNF by peripheral blood mononuclear cells (PBMCs).

Materials and Methods

Patients

We enrolled 52 patients with RA meeting the 1987 American College of Rheumatology criteria and 21 patients meeting the modified New York criteria for AS. They were all receiving follow-up at the department of Rheumatology in the University Hospital of Besançon, France. In RA, disease activity and functional impairment were evaluated using the DAS28 score and Health Assessment Questionnaire (HAQ), respectively. Low disease activity was defined by a DAS28 < 3.2, moderate disease activity by a DAS28 ≥ 3.2 and ≤ 5.1 and high disease activity by a DAS28 > 5.1. For AS, clinical activity was evaluated using the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), the Ankylosing Spondylitis Disease Activity Score (ASDAS-CRP score) and the Bath Ankylosing Spondylitis Functional Index (BASFI). Erythrocyte sedimentation rate (ESR), C reactive protein (CRP) levels and circulating TNF were used as laboratory parameters to assess inflammation. Positivity for rheumatoid factors, anti-CPP antibodies and HLA-B27 status were also recorded. In the RA group, patients were receiving low dosage corticosteroids (< 10 mg prednisone daily) and/or traditional DMARDs (methotrexate, leflunomide, sulfasalazine or hydroxychloroquine). In the AS group, all patients received non-steroidal anti-inflammatory drugs (NSAIDs) and some of them had sulfasalazine or methotrexate. At the time of inclusion, no RA or AS patients were receiving TNF blocking agents or other biologics.

Control subjects

The control group consisted of 38 healthy subjects without inflammatory conditions or treatment. All the patients and healthy controls (HC) gave their written informed consent to participate in the study according to the Helsinki declaration. The study protocol was approved by the local ethics committee (Comité de Protection des Personnes EST-2, study registered under the number 08/498).

Peripheral blood mononuclear cell isolation and cell lysate preparation

PBMCs were prepared from the peripheral blood of patients and HC and were cultured in RPMI-1640 medium supplemented with 10% (v/v) pooled AB human serum (Sigma), as previously described [8]. Isolation of nuclear and cytoplasmic extracts was performed as previously described [9]. Cells were washed with wash buffer (10 mM HEPES, pH 7.6, 10 mM KCl, 2 mM MgCl₂, 1 mM EDTA). Cell pellets were then incubated on ice with cytoplasmic isolation buffer (10 mM HEPES, pH 7.6, 10 mM KCl, 2 mM MgCl₂, 1 mM EDTA, 0.02% NP-40). Cytoplasmic extracts were collected by centrifugation and the nuclear pellets were washed twice in wash buffer, spun, and incubated for 15 min on ice with nuclear isolation buffer (20 mM HEPES pH 7.6, 420 mM NaCl, 1.5 mM MgCl₂, 0.2 mM EDTA, 25% glycerol). Supernatants containing nuclear extracts were collected by centrifugation and stored at -80° C. Protease inhibitors (1 mM DTT, 1 mM PMSF, 1 microg/ml aprotinin, 1 microg/ml leupeptin, 1 microg/ml pepstatin) were added to all solutions. Protein concentration in nuclear and cytoplasmic extracts was determined by the Bradford method using a BioPhotometer (Eppendorf, Hamburg, Germany).

HAT and HDAC activities

The EpizQuik™ HDAC Activity Assay colorimetric kit (Epigentek, Farmingdale, NY) and the HAT activity assay kit (Enzo Life Sciences, Koropi, Greece) were used to evaluate HAT/HDAC activities in PBMC nuclear extracts. Global HDAC activity was evaluated. These activities were measured prior to and after ex vivo exposure of PBMCs to the following HDACi: trichostatin A (TSA), a Class I and Class II inhibitor (1 microM), and sirtinol (Sirt), a sirtuin inhibitor (10 microM). The use of
concentrations of TSA up to 1 microM has been previously reported in studying the effect of HDACi on macrophages and monocytoid cells [10,11].

Circulating TNF and production of TNF by PBMCs
Circulating TNF was evaluated in sera from patients and HC using an ELISA assay (Quantikine assay, R&D Systems, Minneapolis, MN). PBMCs from HC and from patients with RA or AS were treated or not with TSA (1 microM) or Sirt (10 microM), and TNF production in supernatants was measured by ELISA after one and three days of culture.

Regulation of transcription from the human TNF (huTNF) promoter in the presence of HDACi
To assess the epigenetic regulation of the huTNF promoter, U937 cells (ATCC) were transiently transfected with 20 microg of a plasmid expressing the luciferase gene under the control of the huTNF promoter, pTNF-Luc (a gift from Dr D. Kwiatkowski, International Child Health Group, University Department of Pediatrics, John Radcliffe Hospital, Oxford, UK) [12] using electroporation system according to the manufacturer’s instructions (BioRad, Hercules, CA) [9]. Twenty-four hours later, the cells were treated with TSA (1 microM) or Sirt (10 microM). At 24 hrs post-treatment, luciferase activity was measured in cell lysates using a luminometer (TD-20/20; Promega, Madison, WI) as previously described [9]. Values normalized to protein concentrations were expressed in fold increase over unstimulated control values.

Detection of apoptosis
PBMCs (2X10⁶/ml) were remained untreated or treated with TSA (1 microM) and Sirtinol (10 microM) for 24 or 72 h. The cells were washed in cold phosphate-buffered saline (1X PBS), supernatant was discarded and 10⁵ PBMCs were resuspended in 1 ml 1X annexin binding buffer. 5 micro of FITC labeled annexin V (BD Pharmingen™, San Diego, CA) was incubated in 100 microl of resuspended PBMCs. After 15 min incubation at room temperature in the dark, 400 microl of 1X annexin binding buffer was added and 10,000 cells were acquired by FACSCalibur with CELLQuest software (BD Biosciences, Mountain View, CA) [13].

Cell viability assay
Cell viability was measured using the MTT assay kit (Cayman Chemical, Ann Arbor, MI). PBMCs were seeded at a density of 0.1X10⁶/well in triplicates in 96-well plates in a final volume of 100 microl medium containing TSA (1 microM) or Sirtinol (10 microM). Cell culture medium without cells was used as a blank. After 24 hrs or 72 hrs, 10 microl MTT reagent was added to each well and the plates were incubated for another 4 h in the cell culture incubator at 37° C. The plate was centrifuged at 500 g for 10 min. The cell culture media was aspirated and 100 microl crystal dissolving solution was added to each well and the absorbance was measured at 570 nm using Multiskan Ex (Thermo Electron Corporation, France).

Statistical analysis
Results were expressed as mean ± standard error of the mean (SEM). Non-parametric tests were used. Statistical analysis between the three groups (RA, AS and HC) involved non-parametric analysis of variance (ANOVA) using the Kruskal-Wallis test. This test was used to compare age, ESR, CRP and circulating TNF. The Mann Whitney test was used for comparing HAT activity (with and without HDACi), HDAC activity (with and without HDACi) and HDAC/HAT ratio between RA and HC and between AS and HC. The Wilcoxon test was used for the paired comparison of spontaneous HAT or HDAC activity and enzymatic activity under HDACi exposure, and for comparing TNF production in PBMC culture with and without HDACi. Qualitative data (gender) were analyzed using the Chi-squared test. A Spearman’s r-test was used to calculate correlations between HAT and HDAC activities and indices of AS or RA disease activity. Values of p less than 0.05 were considered significant.

Results
Clinical characteristics of the studied population
Patients with RA had mild disease activity (DAS28 > 3.2) while disease was more active in AS patients (BASDAI > 4 and ASDAS > 2.1). Most of the laboratory parameters of inflammation investigated (ESR, CRP and TNF) were elevated in RA and AS compared to HC (Table 1).

HAT and HDAC activities were reduced in patients with AS
HAT activity was lower in AS compared to HC (68.2 ± 8.4 vs 111.3 ± 15.5 ng/h/mg; p = 0.05) while it was higher in RA, but the difference was not significant (126.8 ± 14.6 vs 111.3 ± 15.5 ng/h/mg; p > 0.05) (Table 2, Figure 1A). For HDAC, both AS and RA had decreased levels of activity, and again the difference was only significant between AS and HC (AS vs RA vs HC: 1984.6 ± 249 vs 3915.9 ± 790.3 vs 4778.9 ± 752.3 pmol/min/mg; AS vs HC: p = 0.01; RA vs HC: p > 0.05) (Table 2, Figure 1B). When examining the balance between deacetylation and acetylation, the HDAC/HAT ratio decreased in both RA and AS compared to HC, but without significant differences (all p > 0.05). ESR and CRP did not correlate with HAT or HDAC levels. However, TNF weakly correlated with HDAC activity in AS patients (p = 0.02). Interestingly, in RA patients with high disease activity and compared to patients with low disease activity, we observed a decreased HDAC activity (1009.3 ± 113.1 vs 2230.7 ± 254.3 pmol/min/mg; p = 0.01) (Figure 1C), an enhanced HAT activity (215.2 ± 57.2 vs 115.6 ± 42.5 ng/h/mg; NS) and a decreased ratio of HDAC/HAT activity (13.1 ± 8.2 vs 23.7 ± 12.6; NS).

Results were given as spontaneous activities and after ex vivo treatment of PBMCs by HDAC inhibitors (RA: rheumatoid arthritis; AS: ankylosing spondylitis; HC healthy controls; TSA: trichostatin A; Sirt: sirtinol) (* Mann-Whitney test; ** Wilcoxon test).
HDACi tended to induce changes in HDAC levels in HC and RA but not in AS

In HC, the ex vivo addition of TSA or Sirt on PBMCs did not induce a change in HAT activity (all p > 0.05). Conversely, there was a reduction in HDAC levels that was more evident with Sirt (51.1% reduction), but the results did not reach significance (p = 0.07). In the RA group, TSA induced a non-significant increase in HAT, while there was a modest but significant decrease in this activity under Sirt (p = 0.01). In addition, a 37.7% reduction in HDAC was observed with TSA or Sirt without significance (all p > 0.05). In PBMCs from AS patients, neither HAT nor HDAC activities were influenced by HDACi exposure (all p > 0.05) (Figure 1A and 1B).

Influence of HDACi on TNF production by PBMCs

We then evaluated the influence of HDACi on TNF production by PBMC culture. In HC, TSA reduced TNF release but without significance at day one or three (all p > 0.05). Conversely, Sirt was more effective in reducing TNF production after one (p = 0.03) and three days (p = 0.002). In RA, these effects were less evident, with an increase in TNF at day one with TSA (p = 0.02) and a slight but non-significant decrease in TNF release at day three. Sirt had no effects on TNF production in RA. In AS, only Sirt induced a decline in TNF production at day one (p = 0.017) and three (p = 0.07) while

### Table 1. Clinical and laboratory characteristics of the studied patients with rheumatoid arthritis, ankylosing spondylitis and healthy controls.

|                | RA (n=52) | AS (n=21) | HC (n=38) | P (##)         |
|----------------|-----------|-----------|-----------|---------------|
| **Age (years)**| 56.9 ± 1.5| 44.3 ± 3.2| 34.6 ± 1.8| < 0.0001      |
| **Disease duration (years)**| 11.4 ± 1.2| 14.1 ± 2.2|           |               |
| **Sex**        |           |           |           |               |
| M/F            | 16/36     | 18/3      | 12/26     | < 0.0001      |
| **DAS28**      | 3.8 ± 0.2 |           |           |               |
| **HAQ**        | 1.09 ± 0.1|           |           |               |
| **BASDAI**     |           |           |           |               |
| **ESR (mm/h)** | 23.8 ± 2.8| 27.3 ± 6.5| 7.8 ± 1.5 | < 0.0001      |
| **CRP mg/L**   | 16.1 ± 5.8| 20.4 ± 7.9| 2.7 ± 0.6 | < 0.0001      |
| **Positive Rheumatoid factors** |           |           |           |               |
| N and (%)      | 42 (81)   |           |           |               |
| **Positive anti CPP antibodies** |           |           |           |               |
| N and (%)      | 34 (65.4) |           |           |               |
| **HLA-B27**    | 19 (36)   |           |           |               |
| **Treatments** |           |           |           |               |
| **NSAIDs**     | 17 (81)   |           |           |               |
| **Corticosteroids** | 35 (67) | 1 (4.7) | 6.4 ± 1.5 | [5]           |
| **MTX**        | 28 (54)   | 1 (4.7)   |           |               |
| **DMARDs others** | 19 (36) | 2 (9.5) |           |               |

RA: rheumatoid arthritis; AS: ankylosing spondylitis; HC: healthy controls; DAS28: disease activity score 28 joints; HAQ: health assessment questionnaire; BASDAI: Bath ankylosing spondylitis disease activity index; ASDAS: ankylosing spondylitis disease activity score; BASFI: Bath ankylosing spondylitis functional index; ESR: erythrocyte sedimentation rate; MTX: methotrexate; #: Kruskall-Wallis test

### Table 2. Histone acetyl transferase (HAT) and histone deacetylase (HDAC) activities in PBMC nuclear extracts from patients with rheumatoid arthritis, ankylosing spondylitis and healthy controls.

|                | RA (n=52) | AS (n=21) | HC (n=38) | P (##)         |
|----------------|-----------|-----------|-----------|---------------|
| **HAT (ng/h/mg)**|           |           |           |               |
| (mean ± SEM)    | 126.8 ± 16.4| 68.2 ± 8.1| 111.3 ± 15.5| RA vs HC: NS*  |
| **HDAC (pmol/min/mg)**|           |           |           |               |
| (mean ± SEM)    | 3915.9 ± 790.3| 1984.6 ± 249.0| 4776.9 ± 752.3| RA vs HC: NS*  |
| **Ratio HDAC/HAT**|           |           |           |               |
| (mean ± SEM)    | 49.1 ± 16.7| 35.6 ± 6.9| 65.4 ± 16.7| NS*           |
| **HAT + TSA (ng/h/mg)**|           |           |           |               |
| (mean ± SEM)    | 153.2 ± 30.3| 81.2 ± 9.9| 112.6 ± 21| HAT vs HAT + TSA**; HC: NS |
| **HAT + Sirt (ng/h/mg)**|           |           |           |               |
| (mean ± SEM)    | 113.1 ± 14.0| 71.9 ± 6.2| 107.9 ± 15.9| HAT vs HAT + Sirt**; HC: NS |
| **HDAC + TSA (pmol/min/mg)**|           |           |           |               |
| (mean ± SEM)    | 2457.1 ± 2134.2| 3450.6 ± 709.1| 790.1 | HDAC vs HDAC + TSA**; HC: NS |
| **HDAC + Sirt (pmol/min/mg)**|           |           |           |               |
| (mean ± SEM)    | 2440.6 ± 466.3| 2341.6 ± 242.7| 790.1 | HDAC vs HDAC + Sirt**; HC: p = 0.07 |

RA: rheumatoid arthritis; AS: ankylosing spondylitis; HC: healthy controls; DAS28: disease activity score 28 joints; HAQ: health assessment questionnaire; BASDAI: Bath ankylosing spondylitis disease activity index; ASDAS: ankylosing spondylitis disease activity score; BASFI: Bath ankylosing spondylitis functional index; ESR: erythrocyte sedimentation rate; MTX: methotrexate; #: Kruskall-Wallis test
TSA tended to induce TNF production at day one (Figure 2A and 2B). In parallel with this TNF production at day one post-treatment with TSA in RA and AS, there was higher TNF gene expression in the monocytoid U937 cells transiently transfected, with a plasmid expressing the luciferase gene under the control of the huTNF promoter and treated with TSA. Conversely, there was no variation in TNF gene expression in the same cells under Sirt treatment (Figure 3).

**Detection of apoptosis and cell viability in PBMCs from healthy controls:** Apoptosis was then assessed in HC PBMCs treated with TSA or Sirt using annexin-V assay. TSA and to a much lesser extent Sirt triggered apoptosis in HC PBMCs, mostly in peripheral blood lymphocytes (PBLs), after 1 and 3 days of treatment (Figure 4A). In parallel, decreased viability of HC PBMCs using a MTT assay was observed, mostly with TSA treatment (Figure 4B).

**Discussion**

Few studies have evaluated the equilibrium between HAT and HDAC activities in RA and there is no available data in AS [4,6,14]. This study was thus undertaken in order to clarify the balance between HDAC and HAT activities and to determine its influence on PBMC TNF production. Our results showed that HDAC/HAT activities were clearly disturbed in AS, with a significant reduction in both HAT and HDAC activities. In this patient group, the resulting balance in HDAC/HAT activities was also reduced compared to HC (but without significance) but this may be explained by the parallel decrease in both HAT and HDAC activities. By contrast, RA patients were characterized by a non-significant increase in HAT activity and a parallel decrease in HDAC, resulting in a reduced HDAC/HAT ratio. Interestingly, when we studied sub-populations of RA patients taken into account their DAS28 score, we observed that RA patients with high disease activity displayed significant decreased HDAC activity, with a parallel but non significant enhanced HAT activity and decreased...
Limited data are available on the levels of HAT or HDAC activities in PBMC extracts from patients with RA. Gillespie et al. evaluated HAT and HDAC activities in PBMCs in a limited series of patients with RA (N = 8) and found increased HDAC activity but no changes in the levels of HAT compared to HC [15]. Besides these results, HAT or HDAC have been assessed in synovial tissue samples from RA patients. Conflicting results were reported, with decreased [16] or increased expression of HDAC [17,18] in synovial tissue from patients with RA compared to patients with osteoarthritis. These contradictory results may be explained in part by the disease duration of the patients evaluated and the treatment.

**Figure 2. Quantification of TNF production in HC, RA and AS subjects.** TNF production by PBMCs from healthy controls (N = 13) and patients with rheumatoid arthritis (N = 10) or ankylosing spondylitis (n = 21) after one (day one) (A) and three days (day three) (B) of cell culture. TNF was measured by ELISA in the culture supernatant without (control) and with histone deacetylase inhibitors: trichostatin A (TSA) or sirtinol (Sirt). Results were expressed as mean ± SEM (HC: healthy controls; RA: rheumatoid arthritis; AS: ankylosing spondylitis).

doi: 10.1371/journal.pone.0070939.g002
given, especially TNF blocking agents, and the biopsy samples evaluated (total synovium versus synovial fibroblasts). Low HDAC activity in RA synovial tissue was interpreted as a factor of hyperacetylation that can contribute to the activation of gene coding for pro-inflammatory cytokines and thus to the pathogenesis of RA [16]. Alternatively, high levels of HDAC (in PBMCs or synovial tissue) in RA may perpetuate inflammation by activating the RA synovial fibroblasts to produce mediators of joint damage [15,17,18]. In this sense, the levels of HDAC1 activity in synovial tissue correlated with the amount of cytoplasmic TNF [17]. It has also been reported that increased HDAC activity in synovial tissue may decrease expression of cell-cycle related molecules such as p16, p21 and p53 [18]. Presumably, the mechanisms linking HDAC activity to inflammatory mechanisms are mainly explained by non-histone modifications and by its influences on transcription factors [4,7,19]. For instance, it has been demonstrated that the subunits of the NF-kappaB signaling pathway, including the inhibitory transcription factor I-kappaB, are acetylated/deacetylated, and thus is influenced by the enzymatic couple HDAC activity [4,7]. High HDAC activity in this context may therefore maintain deacetylated such inhibitory factor allowing for NF-kappaB activation [19]. In AS, both HDAC and HAT were significantly reduced, with the resulting balance between HDAC and HAT also lower. This hyperacetylation status may also favor pro-inflammatory processes and ultimately contribute to AS pathogenesis.

In our study we also evaluated the ex vivo influence of HDACi on PBMC HAT/HDAC expression. Our results showed a decline, albeit not significant, in HDAC activity with TSA and Sirt in HC, while in RA, Sirt was able to reduce HAT. HDAC activity was also regulated in RA by TSA and Sirt, without reaching significance. By contrast, AS patients were not sensitive to TSA or Sirt. Trichostatin A is a pan-HDACi, inhibiting both Class I and Class II HDAC. We did not use specific HDACi in our study. HDAC1 and HDAC2 have been identified as the main HDAC Class I isoenzymes expressed within the synovium of patients with RA [17,18]. The NF-kappaB heterodimer composed of RelA/p65 and p50 proteins interacts with HDAC1 and HDAC2 [19]. Additionally, the localization of both RelA/p65 and sirtuin 1 proteins on the gene promoter suggests that sirtuin 1 may actively repress the gene expression by deacetylating RelA/p65 directly on chromatin [20], making the regulation of NF-kappaB-dependent genes even more complex. Finally, an imbalance of inflammatory and antiinflammatory macrophages has been reported in RA synovium [21]. The reestablishment of macrophage equilibrium by eliminating the proinflammatory macrophages could be an effective therapeutic approach for RA. Preclinical studies have shown the therapeutic efficacy of an anti-human death receptor 5 (DR5) antibody called TRA-8 in eliminating a subpopulation of inflammatory macrophages which produce high levels of cytokines, including TNF [21]. Thus, further data are needed to better understand HDACi influence on the regulation of HAT/HDAC in RA. Also, it would be more effective to target these specific HDAC activities by selective inhibitors in specific cell types, such as inflammatory macrophages.

It has previously been shown that HDACi may regulate cytokine production [4,7,22–24]. When evaluating the influence of HDACi on the production of TNF by PBMCs in our patients, we observed that Sirt was more effective compared to TSA for reducing TNF in HC. Since HDACi have been reported to trigger apoptosis [25–28] and thereby could influence TNF production in cell culture, we assessed apoptosis in HC...
PBMCs treated with TSA or Sirt using annexin-V assay. We observed that TSA and to a much lesser extent Sirt trigger apoptosis in HC PBMCs after 1 and 3 days of treatment. In agreement with these data, we also observed decreased viability of HC PBMCs using a MTT assay, mostly with TSA treatment. Although we cannot exclude that the observed decreased TNF production in our cultures is due to enhanced apoptosis triggered by HDACi, we believe that it cannot be explained primarily by cell apoptosis. First, the most important TNF decrease in our cultures is observed with Sirt treatment, although Sirt triggers only limited PBMC apoptosis and cell viability is quite high under Sirt treatment. Second, TNF is produced mostly by monocytes/macrophages rather than by PBLs, and we observed a preferential apoptosis of PBLs under HDACi treatment, as reported previously by others [25,26]. The reduction of TNF production was not significant in the RA group, while in AS, Sirt significantly reduced TNF production.

The limited reduction of TNF production in our cultures could be explained by the fact that HDACi have only limited effects on immune cells not exposed to activating stimuli (for instance LPS) and their anti-inflammatory effects become apparent only after stimulation [26,29]. In agreement with this hypothesis, HDACi including TSA inhibit cytokine release (TNF, IL-6 and IL-12) by bone marrow derived macrophages exposed to microbial products and bacteria such as LPS and heat-killed E. Coli and S. Aureus [30,31]. Inhibition of TNF production has also been reported in PBMCs stimulated with LPS (10 ng/ml) one hour after preincubation with the HDACi SAHA [32]. Therefore, the in vitro activation of immune cells might have given a more pronounced effect of HDACi on TNF production.

In conclusion, we observed a disturbed balance of HDAC and HAT activity in our patients with AS and, to a lesser degree, in RA. Ex vivo exposure of PBMCs to HDACi could modulate these activities, mainly in HC, but also in RA. TNF production could be regulated by HDACi treatment, especially...
Acknowledgements

The authors are indebted Mrs Frances Sheppard, Clinical Investigation Center Biotherapy CBT-506, University Hospital Besançon, France, for her help in preparing the manuscript.

Author Contributions

Conceived and designed the experiments: ET GH. Performed the experiments: WA KAK MT AJ LB. Analyzed the data: ET GH. Wrote the manuscript: ET GH. Enrolled the patients: ET DW EB.

References

1. Toussriot E, Khan KA, Bertolini E, Wendling D, Herbein G (2010) Histone deacetylase inhibitors: new treatment options for inflammatory joint disease? Joint Bone Spine 77: 395-398. doi:10.1016/j.jbspin.2010.03.009. PubMed: 20729120.
2. Huber LC, Stanczyk J, Jüngel A, Gay S (2007) Epigenetics in inflammatory rheumatic diseases. Arthritis Rheum 56: 3523-3531. doi: 10.1002/art.22948. PubMed: 17968222.
3. Striehoff S, Maurer B, Peters MA, Pap T, Gay S (2008) Epigenetic modifications in rheumatoid arthritis. Arthritis Res Ther 10: 219. doi: 10.1186/ar2500. PubMed: 18947370.
4. Grabiec AM, Tak PP, Reedquist KA (2008) Targeting histone deacetylation activity in rheumatoid arthritis and asthma as prototypes of inflammatory disease: should we keep our HATs on? Arthritis Res Ther 10: 226. doi:10.1186/ar2489. PubMed: 18983693.
5. Blanchard F, Chippy C (2005) Histone deacetylase inhibitors: new drugs for the treatment of inflammatory diseases? Drug Discov Today 10: 197-204. doi:10.1016/S1359-6446(04)33094-9. PubMed: 15708534.
6. Rosato RR, Grant S (2004) Histone deacetylase inhibitors in clinical development. Expert Opin Investig Drugs 13: 21-38. doi: 10.1517/13543784.13.1.21. PubMed: 14680455.
7. Grabiec AM, Tak PP, Reedquist KA (2011) Function of histone deacetylase inhibitors in inflammation. Crit Rev Immunol 31: 233-263. doi:10.1615/CritRevImmunol.v31.i3.40. PubMed: 21740352.
8. Khan KA, Coaquette A, Davrinche C, Herbein G (2009) Bid-3-regulated transcription from major immediate-early promoter of human cytomegalovirus in monocyte-derived macrophages. J Immunol 182: 7784-7794. doi:10.4049/jimmunol.0803800. PubMed: 19494302.
9. Varin A, Mannia SK, Quivy V, Decron AZ, Van Lint C et al. (2003) Exogenous Nef protein activates NF-kappaB, AP-1, and c-Jun N-terminal kinase and stimulates HIV transcription in promonocytic cells. Role Aids Pathog J Biol Chem 278: 2219-2227.
10. Zhang F, Shi Y, Wang L, Siram S (2011) Role of HDAC3 on p53 expression and apoptosis in T cells of patients with multiple sclerosis. PLOS ONE 6: e16795. doi:10.1371/journal.pone.0016795. PubMed: 21348816.
11. Reuse S, Calao M, Kabeya K, Guiuken A, Gatot JS et al. (2009) Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: implications for treatment of latent infection. PLOS ONE 4: e6093. doi:10.1371/journal.pone.0006093. PubMed: 19564922.
12. Kuprash DV, Udalova IA, Turetskaya RL, Kurosaka M et al. (2009) Expression and function of histone deacetylase 3-selective inhibitor reduces interleukin-6 production by peripheral blood mononuclear cells from rheumatoid arthritis patients. Arthritis Rheum 64: 418-422. doi:10.1002/art.33382. PubMed: 21952924.
13. Huber LC, Brock M, Hemmatzad H, Giger OT, Moritz F et al. (2007) Histone deacetylase/acetylase activity in total synovial tissue derived from rheumatoid arthritis and osteoarthritis patients. Arthritis Rheum 56: 1087-1093. doi:10.1002/art.22512. PubMed: 17393417.
14. Kawabata T, Nishida K, Takasugi K, Ogawa H, Sada K et al. (2010) Increased activity and expression of histone deacetylase 1 in relation to tumor necrosis factor-alpha in synovial tissue of rheumatoid arthritis. Arthritis Res Ther 12: R133. doi:10.1186/ar3092. PubMed: 20609223.
15. Horiuchi M, Morinobu A, Chin T, Sakai Y, Kurosaka M et al. (2009) Expression and function of histone deacetylases in rheumatoid arthritis synovial fibroblasts. J Rheumatol 36: 1580-1589. doi:10.3899/jrheum.081115. PubMed: 19531758.
16. Ashburner BP, Westerheide SD, Baldwin AS Jr. (2001) The p56 (RhoA) subunit of NF-kappaB interacts with the histone deacetylase (HDAC) corepressors HDAC1 and HDAC2 to negatively regulate gene expression. Mol Cell Biol 21: 7065-7077. doi:10.1128/MCB.21.20.7065-7077.2001. PubMed: 11564889.
17. Fusco S, Maulucci G, Pani G (2012) Sirt1: def-eating senescence? Cell Cycle 11: 4135-4146. doi:10.4161/cc.22074. PubMed: 22938125.
18. Li J, Hsu HC, Yang P, Wu Q, Li H et al. (2012) Treatment of arthritis by macrophage depletion and immunomodulation: testing an apoptosis-mediated therapy in a humanized death receptor mouse model. Arthritis Rheum 64: 1098-1109. doi:10.1002/art.33423. PubMed: 22006294.
19. Lin HS, Hu CY, Chan HY, Liew YY, Huang HP et al. (2007) Anti-rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collagen-induced arthritis in rodents. Br J Pharmacol 150: 862-872. doi:10.1038/jjp.2007.165. PubMed: 17325656.
20. Nasu Y, Nishida K, Miyazawa S, Komiya Y, Kadota Y et al. (2008) Trichostatin A, a histone deacetylase inhibitor, suppresses synovial inflammation and subsequent cartilage destruction in a collagen antibody-induced arthritis mouse model. Osteoarthritis Cartilage 16: 723-732. doi:10.1016/j.joca.2007.10.014. PubMed: 18226559.
21. Vojinovic J, Damjanov N (2011) HDAC inhibition in rheumatoid arthritis and juvenile idiopathic arthritis. Mol Med 17: 397-403. PubMed: 21390915.
22. Glauben R, Batra A, Fedke I, Zeltz M, Lehr HA et al. (2006) Histone hyperacetylation is associated with amelioration of experimental colitis in mice. J Immunol 176: 5015-5022. PubMed: 16585598.
23. Grabiec AM, Krausz S, de Jager W, Burakowski T, Groot D et al. (2010) Histone deacetylase inhibitors suppress inflammatory activation of rheumatoid arthritis patient synovial macrophages and tissue. J Immunol 184: 2718-2728. doi:10.4049/jimmunol.0901467. PubMed: 2100935.
24. Leoni F, Fossati G, Lewis EC, Lee JK, Porro G et al. (2005) The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivo. Mol Med 11: F-15. doi:10.2119/2006-00005.Dinarello. PubMed: 16557334.
25. Niederer F, Oppelt C, Brentano F, Hottinger MO, Gay RE et al. (2011) SIRT1 overexpression in the rheumatoid arthritis synovium contributes to pro-inflammatory cytokine production and apoptosis resistance. Ann Rheum Dis 70: 1866-1873. doi:10.1136/ard.2010.148957. PubMed: 21742641.
26. Halli MA, Andrews MR, Labzin LI, Schroder K, Matthias G et al. (2010) Differential effects of selective HDAC inhibitors on macrophage inflammatory responses to the Toll-like receptor 4 agonist LPS. J Leukoc Biol 87: 1103-1114. doi:10.1189/jlb.0509263. PubMed: 20100315.
27. Roger T, Lugin J, Le Roy D, Goy M, Lombelli M et al. (2011) Histone deacetylase inhibitors impair innate immune responses to Toll-like receptor agonists and to infection. Blood 117: 1205-1217. doi:10.1182/blood-2010-05-294711. PubMed: 20956800.
31. Mombelli M, Lugrin J, Rubino I, Chanson AL, Giddey M et al. (2011) Histone deacetylase inhibitors impair antibacterial defenses of macrophages. J Infect Dis 204: 1367-1374. doi:10.1093/infdis/jir553. PubMed: 21921209.

32. Leoni F, Zaliani A, Bertolini G, Porro G, Pagani P et al. (2002) The anti-tumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits anti-inflammatory properties via suppression of cytokines. Proc Natl Acad Sci U S A 99: 2995-3000. doi:10.1073/pnas.052702999. PubMed: 11867742.

33. Shen Z, Ajmo JM, Rogers CQ, Liang X, Le L et al. (2009) Role of SIRT1 in regulation of LPS- or two ethanol metabolites-induced TNFalpha production in cultured macrophage cell lines. Am J Physiol Gastrointest Liver Physiol 296: G1047-G1053. doi:10.1152/ajpgi.00016.2009. PubMed: 19299582.

34. Mahlknecht U, Will J, Varin A, Hoelzer D, Herbein G (2004) Histone deacetylase 3, a class I histone deacetylase, suppresses MAPK11-mediated activating transcription factor-2 activation and represses TNF gene expression. J Immunol 173: 3979-3990. PubMed: 15356147.

35. Vojinovic J, Damjanov N, D’Urzo C, Furlan A, Susic G et al. (2011) Safety and efficacy of an oral histone deacetylase inhibitor in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 63: 1452-1458. doi:10.1002/art.30238. PubMed: 21538322.